Dabur India Limited · NSE:DABUR
Dabur India — Q4 FY21 Earnings Presentation
28 slides from Dabur India's earnings presentation, May 7, 2021
Slide 1: Exchange filing cover letter
Ref: SEC/SE/2021-22 ed Date: May 7, 2021 India Ltd. Scrip Symbol: NSE- DABUR, BSE Scrip Code: 500096 To, Corporate Relation Department National Stock Exchange of India Ltd. BSE Ltd. Exchange Plaza, 5th Floor Phiroze Jeejecbhoy Towers Plot No. C/1, G Block Bandra - Kurla Complex Dalal Street, Mumbai-
Slide 2: Q4 FY21 and FY21 Results Presentation
Q4 FY21 and FY21 – Results Presentation 7th May 2021
Slide 3: Agenda
Agenda 1. 2. 3. 4. FY21 – Q4 FY21 – Business Dividend Performance Performance Highlights Update Overview Overview 2
Slide 4: Agenda
Agenda 1. 2. 3. 4. FY21 – Q4 FY21 – Business Dividend Performance Performance Highlights Update Overview Overview 3
Slide 5: FY21 – Performance Summary
FY21 – Performance Summary Consolidated Revenue Growth 9.9% India FMCG Growth 14.7% 12.4% India FMCG Volume Growth International Business Growth 3.4% Operating Profit Growth 11.7% Consolidated PAT Growth 17.2% 4
Slide 6: FY21 – Financials
FY21 – Financials Revenue +9.9% 9,562 8,704 • India FMCG saw 14.7% growth on the back of 12.4% volume growth • Growth in International Business was 3.4% FY20 FY21 Operating Profit • Consolidated Operating Profit crossed INR 2,000 cr for the first time, recording a growth +11.7% 2,003 of 11.7% 1,792
Slide 7: Domestic FMCG Growth – By Verticals – FY21
Domestic FMCG Growth – By Verticals – FY21 FY20 Sales Contribution FY21 Sales Contribution Food and Food and Beverage Healthcare Beverage 33.9% Healthcare 15.9% 13.1% 39.0% HPC HPC 50.1% 47.9% Healthcare Home & Personal Care (HPC) Food and Beverage (F&B) Growth: 31.9% Growth: 9.5% Growth: (5.7%) Ex-
Slide 8: Innovation (Domestic Business) – FY21
Innovation (Domestic Business) – FY21 Health Care HPC Foods E-comm First 7x
Slide 9: International Business – FY21 Performance
International Business – FY21 Performance FY20 Sales Contribution Others 3.3% International International Business reported growth of 3.4% 28.2% Domestic FY21 Constant Currency Growth % 68.6% 25.7% 24.2% 4.4% 0.9% 0.8% FY21 Sales Contribution (4.9%) Others (11.2%) International 2.3% MENA Egypt SSA H
Slide 10: Innovation (International Business) – FY21
Innovation (International Business) – FY21 9
Slide 11: Agenda
Agenda 1. 2. 3. 4. FY21 – Q4 FY21 – Business Dividend Performance Performance Highlights Update Overview Overview 10
Slide 12: Q4 FY21 – Performance Summary
Q4 FY21 – Performance Summary Consolidated Revenue Growth 25.3% India Standalone Growth 30.3% 25.4% India FMCG Volume International Business Growth 19.4% Growth Operating Profit Growth 25.6% Consolidated PAT Growth 34.4% 11
Slide 13: Q4 FY21 – Financials
Q4 FY21 – Financials Revenue +25.3% 2,337 1,865 • Standalone business revenue grew by 30.3% on the back of 25.4% volume growth • Growth in International Business was 19.4% with constant currency growth of 21% Q4 FY20 Q4 FY21 Operating Profit +25.6% • Consolidated Operating Profit saw a growth of 25.
Slide 14: Domestic FMCG Growth – By Verticals
Domestic FMCG Growth – By Verticals – Q4 FY21 Q4 FY20 Sales Contribution Q4 FY21 Sales Contribution Food and Food and Beverage Healthcare Beverage Healthcare 15.2% 35.4% 15.1% 33.9% HPC HPC 49.4% 51.0% Healthcare Home & Personal Care (HPC) Food and Beverage (F&B) Growth: 22.9% Growth: 32.6% Growth:
Slide 15: International Business Performance
International Business – Q4 FY21 Performance Q4 FY20 Sales Contribution Others 3.5% International Business reported growth of 19.4% with International CC growth of 21% 29.4% Domestic Q4 FY21 Constant Currency Growth % 67.1% 46.7% 24.1% 21.9% 22.0% 21.4% 11.6% Q4 FY21 Sales Contribution Others (0.3%)
Slide 16: Agenda
Agenda 1. 2. 3. 4. FY21 – Q4 FY21 – Business Dividend Performance Performance Highlights Update Overview Overview 15
Slide 17: Healthcare – Q4 FY21
Healthcare – Q4 FY21 Health Supplements Digestives OTC Ethicals Growth % 17.7% 20.0% 34.0% 39.1% • Dabur Chyawanprash • Pudin Hara portfolio posted • Driven by strong growth in • Ethicals grew in strong recorded strong growth double-digit growth in Q4 Lal Tail and Shilajit Portfolio double digits on
Slide 18: Home and Personal Care – Q4 FY21
Home and Personal Care – Q4 FY21 Oral Care Hair Oils Shampoo Home Care Skin & Salon Growth % 42.1% 24.6% 33.4% 24.3% 37.9% • Red Toothpaste • Witnessed a smart • Shampoos portfolio • Odonil reported strong • Driven by strong continued to see good broad based recovery registered strong growth growth
Slide 19: Food and Beverage – Q4 FY21
Food and Beverage – Q4 FY21 Beverages Foods Growth % 27.1% 36.1% • Beverage business witnessed a smart recovery during Q4 • Hommade brand continued to perform well driven by increased in home despite HORECA business remaining under pressure consumption • Market share of Real in JNSD (Juices, Nectar
Slide 20: Agenda
Agenda 1. 2. 3. 4. FY21 – Q4 FY21 – Business Dividend Performance Performance Highlights Update Overview Overview 19
Slide 21: Dividend Update
Dividend Update Interim Final Total Dividend Dividend Dividend Dividend policy changed with Dividend per share (INR) 1.75 3.0 4.75 Payout Ratio at 50% of Dabur India Ltd’s Consolidated Profit after Tax (vs 40% of Consolidated PAT or 50% of Standalone PAT earlier) Dividend % 175% 300% 475% Total divi
Slide 22: Annexure
Annexure
Slide 23: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement All figures are in INR cr Q4 FY21 Q4 FY20 Y-o-Y (%) FY21 FY20 Y-o-Y (%) Revenue from operations 2,336.8 1,865.4 25.3% 9,561.7 8,703.6 9.9% Other Income 85.0 75.7 12.2% 325.3 305.2 6.6% Total Income 2,421.8 1,941.1 24.8% 9,886.9 9,008.8 9.7% Material Cost 1,197.
Slide 24: Standalone Profit and Loss Statement
Standalone Profit and Loss Statement All figures are in INR cr Q4 FY21 Q4 FY20 Y-o-Y (%) FY21 FY20 Y-o-Y (%) Revenue from operations 1,721.9 1,321.2 30.3% 7,184.7 6,309.8 13.9% Other Income 70.5 67.1 5.2% 276.7 276.9 (73.6%) Total Income 1,792.4 1,388.2 29.1% 7,461.4 6,586.7 13.3% Material Cost 924.
Slide 25: Consolidated Balance Sheet
Consolidated Balance Sheet As at As at As at 31/03/2021 As at 31/03/2021 Particulars 31/03/2020 Particulars 31/03/2020 (Audited) (Audited) (Audited) (Audited) A Assets B Equity and Liabilities Non-current 1 Equity 1 assets (a) Equity share capital 177 177 (a) Property, plant and equipment 1,812 1,82
Slide 26: Standalone Balance Sheet
Standalone Balance Sheet As at As at As at 31/03/2021 As at 31/03/2021 Particulars 31/03/2020 Particulars 31/03/2020 (Audited) (Audited) (Audited) (Audited) A Assets B Equity and Liabilities 1 Non-current assets 1 Equity (a) Property, plant and equipment 1,131 1,061 (a) Equity share capital 177 177
Slide 27: Breakdown of Revenue from Operations
Breakdown of Revenue from Operations All figures are in INR crores, unless otherwise stated Q4 FY21 Q4 FY20 Y-o-Y (%) FY21 FY20 Y-o-Y (%) Health Supplements 285 242 17.7% 1,589 1,115 42.5% Digestives 104 87 20.0% 381 372 2.2% OTC & Ethicals 151 110 36.9% 677 518 30.6% Healthcare 541 440 22.9% 2,647
Slide 28: For more information and updates, visit
For more information and updates, visit: http://www.dabur.com/in/en-us/investor